Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | CPA1 | P15085 | 2/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569013 | 1.00 | TAAR1 (0.39) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL20318756 | 0.92 | TAAR1 (0.41) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL20318755 | 0.92 | TAAR1 (0.41) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL20332599 | 0.90 | TAAR1 (0.40) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL4569003 | 0.87 | GGPS1 (0.38) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL4568992 | 0.87 | GGPS1 (0.38) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL4568989 | 0.87 | GGPS1 (0.38) | TAAR1GGPS1MMEACECPA1 | |
| SCHEMBL15150988 | 0.82 | TAAR1 (0.38) | TAAR1GGPS1PPARGPPARAMAPK1 | |
| SCHEMBL15151000 | 0.82 | TAAR1 (0.38) | TAAR1GGPS1PPARGPPARAMAPK1 | |
| SCHEMBL20332001 | 0.82 | TAAR1 (0.40) | TAAR1GGPS1PPARGPPARAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885GGPS1 1244/4885MME 1157/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TAAR1 1482/4885GGPS1 1244/4885MME 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.